Joint CORP 10-Q quarterly reports

The Joint Corp. reported a net income of $1.9 million for the nine months ended September 30, 2025, driven by its refranchising strategy, despite a decrease in comparable same-store sales.

The Joint Corp. reported a net income of $1.06 million for the first six months of 2025, a significant turnaround driven by its refranchising strategy and growth in its franchise operations.

The Joint Corp. filed an amended quarterly report, restating Q1 2025 financial statements due to material errors in asset valuation and disclosing a material weakness in internal controls.

The Joint Corp. announces its Q1 2025 financial results, highlighting a strategic shift towards franchise-focused expansion and the ongoing refranchising of company-owned clinics.

The Joint Corp. announced its Q3 2024 financial results, highlighting a strategic move to re-franchise the majority of its company-owned clinics.

The Joint Corp. reported a net loss for the second quarter of 2024, while continuing its strategic shift towards re-franchising company-owned clinics.

The Joint Corp. saw a 5% increase in total revenue in Q1 2024, driven by growth in both company-owned and franchised clinics, while also progressing with its strategic re-franchising plan.